Raisio (RAIKV) Q1 2026 earnings summary

Executive summary

• Earnings improved significantly in Q1 2026, with strong gains in profitability and cash flow despite flat sales and ongoing ERP renewal costs.

• Growth was driven by the Breakfast, Snacking & Food Solutions segment, supported by new product launches and international expansion.

• The Heart Health unit underperformed due to currency headwinds and inventory valuation, but improvement measures are underway.

• Strategic investments and brand launches, including Elovena and Benecol®, supported ongoing growth.

Financial highlights

• Net sales reached €57.5 million, up 0.7% year-over-year; comparable EBIT rose 22.7% to €8.5 million.

• Comparable EBITDA rose 15% to €9.8 million (17.0% of sales); EBIT was €8.2 million (14.3% of sales).

• Comparable EPS increased to €0.04 from €0.03; cash flow improved to €8.3 million.

• Return on invested capital rose to 11.3% from 10.1% year-over-year.

• Equity ratio remained strong at 80.0%.

Outlook and guidance

• Net sales and comparable EBIT for 2026 are projected to increase compared to 2025.

• Dividend policy targets 50-100% payout of annual EPS; €0.15 per share dividend paid for 2025.

• Strategic priorities for 2026 focus on accelerating sales growth and further improving profitability.